Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have received an average recommendation of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $36.90.

A number of equities research analysts recently weighed in on SNDX shares. Stifel Nicolaus boosted their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Citigroup upped their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. UBS Group initiated coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th.

Syndax Pharmaceuticals Stock Down 1.2 %

NASDAQ:SNDX opened at $12.77 on Friday. The company has a market cap of $1.09 billion, a PE ratio of -3.52 and a beta of 0.86. The business’s 50 day moving average is $16.76 and its two-hundred day moving average is $19.07. Syndax Pharmaceuticals has a 52 week low of $12.52 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter last year, the business earned ($0.73) earnings per share. As a group, sell-side analysts expect that Syndax Pharmaceuticals will post -2.39 EPS for the current fiscal year.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Syndax Pharmaceuticals during the second quarter valued at approximately $27,000. Values First Advisors Inc. bought a new position in Syndax Pharmaceuticals during the 3rd quarter valued at $30,000. nVerses Capital LLC acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $33,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter valued at $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).